These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 18235116)

  • 1. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    Gibbons J; Egorin MJ; Ramanathan RK; Fu P; Mulkerin DL; Shibata S; Takimoto CH; Mani S; LoRusso PA; Grem JL; Pavlick A; Lenz HJ; Flick SM; Reynolds S; Lagattuta TF; Parise RA; Wang Y; Murgo AJ; Ivy SP; Remick SC;
    J Clin Oncol; 2008 Feb; 26(4):570-6. PubMed ID: 18235116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group.
    Ramanathan RK; Egorin MJ; Takimoto CH; Remick SC; Doroshow JH; LoRusso PA; Mulkerin DL; Grem JL; Hamilton A; Murgo AJ; Potter DM; Belani CP; Hayes MJ; Peng B; Ivy SP;
    J Clin Oncol; 2008 Feb; 26(4):563-9. PubMed ID: 18235115
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group.
    Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow JH; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Greenslade D; Goetz A; Grem JL
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):20-5. PubMed ID: 14523791
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma.
    Reardon DA; Desjardins A; Vredenburgh JJ; Sathornsumetee S; Rich JN; Quinn JA; Lagattuta TF; Egorin MJ; Gururangan S; McLendon R; Herndon JE; Friedman AH; Salvado AJ; Friedman HS
    Neuro Oncol; 2008 Jun; 10(3):330-40. PubMed ID: 18359865
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma.
    Reardon DA; Egorin MJ; Desjardins A; Vredenburgh JJ; Beumer JH; Lagattuta TF; Gururangan S; Herndon JE; Salvado AJ; Friedman HS
    Cancer; 2009 May; 115(10):2188-98. PubMed ID: 19248046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
    Kelley RK; Hwang J; Magbanua MJ; Watt L; Beumer JH; Christner SM; Baruchel S; Wu B; Fong L; Yeh BM; Moore AP; Ko AH; Korn WM; Rajpal S; Park JW; Tempero MA; Venook AP; Bergsland EK
    Br J Cancer; 2013 Oct; 109(7):1725-34. PubMed ID: 24022191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-escalating and pharmacological study of oxaliplatin in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
    Takimoto CH; Remick SC; Sharma S; Mani S; Ramanathan RK; Doroshow J; Hamilton A; Mulkerin D; Graham M; Lockwood GF; Ivy P; Egorin M; Schuler B; Greenslade D; Goetz A; Knight R; Thomas R; Monahan BP; Dahut W; Grem JL;
    J Clin Oncol; 2003 Jul; 21(14):2664-72. PubMed ID: 12860942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-dose, randomized crossover comparisons of different-strength imatinib mesylate formulations in healthy Korean male subjects.
    Kim KA; Park SJ; Kim C; Park JY
    Clin Ther; 2013 Oct; 35(10):1595-602. PubMed ID: 24060561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
    Dugan E; Truax R; Meadows KL; Nixon AB; Petros WP; Favaro J; Fernando NH; Morse MA; Blobe GC; Hurwitz HI
    Anticancer Res; 2010 Apr; 30(4):1251-6. PubMed ID: 20530436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.
    Cortes J; Jabbour E; Daley GQ; O'Brien S; Verstovsek S; Ferrajoli A; Koller C; Zhu Y; Statkevich P; Kantarjian H
    Cancer; 2007 Sep; 110(6):1295-302. PubMed ID: 17623836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalating and pharmacological study of bortezomib in adult cancer patients with impaired renal function: a National Cancer Institute Organ Dysfunction Working Group Study.
    Leal TB; Remick SC; Takimoto CH; Ramanathan RK; Davies A; Egorin MJ; Hamilton A; LoRusso PA; Shibata S; Lenz HJ; Mier J; Sarantopoulos J; Mani S; Wright JJ; Ivy SP; Neuwirth R; von Moltke L; Venkatakrishnan K; Mulkerin D
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1439-47. PubMed ID: 21479634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy.
    Pishvaian MJ; Slack R; Koh EY; Beumer JH; Hartley ML; Cotarla I; Deeken J; He AR; Hwang J; Malik S; Firozvi K; Liu M; Elston B; Strychor S; Egorin MJ; Marshall JL
    Cancer Chemother Pharmacol; 2012 Dec; 70(6):843-53. PubMed ID: 23014737
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal dysfunction in a renal transplant patient treated concurrently with cyclosporine and imatinib.
    Mulder KE; Egorin MJ; Sawyer MB
    Invest New Drugs; 2012 Dec; 30(6):2400-2. PubMed ID: 22116657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours.
    Adenis A; Ray-Coquard I; Italiano A; Chauzit E; Bui-Nguyen B; Blay JY; Tresch-Bruneel E; Fournier C; Clisant S; Amela EY; Cassier PA; Molimard M; Penel N
    Br J Cancer; 2013 Nov; 109(10):2574-8. PubMed ID: 24149182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of eribulin mesylate in cancer patients with normal and impaired renal function.
    Tan AR; Sarantopoulos J; Lee L; Reyderman L; He Y; Olivo M; Goel S
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1051-61. PubMed ID: 26433580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer.
    Nabhan C; Villines D; Valdez TV; Tolzien K; Lestingi TM; Bitran JD; Christner SM; Egorin MJ; Beumer JH
    Br J Cancer; 2012 Aug; 107(4):592-7. PubMed ID: 22805325
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of pazopanib in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study.
    Shibata SI; Chung V; Synold TW; Longmate JA; Suttle AB; Ottesen LH; Lenz HJ; Kummar S; Harvey RD; Hamilton AL; O'Neil BH; Sarantopoulos J; LoRusso P; Rudek MA; Dowlati A; Mulkerin DL; Belani CP; Gandhi L; Lau SC; Ivy SP; Newman EM
    Clin Cancer Res; 2013 Jul; 19(13):3631-9. PubMed ID: 23653147
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer.
    Connolly RM; Rudek MA; Garrett-Mayer E; Jeter SC; Donehower MG; Wright LA; Zhao M; Fetting JH; Emens LA; Stearns V; Davidson NE; Baker SD; Wolff AC
    Breast Cancer Res Treat; 2011 May; 127(1):153-62. PubMed ID: 21350820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Target-driven exploratory study of imatinib mesylate in children with solid malignancies by the Innovative Therapies for Children with Cancer (ITCC) European Consortium.
    Geoerger B; Morland B; Ndiaye A; Doz F; Kalifa G; Geoffray A; Pichon F; Frappaz D; Chatelut E; Opolon P; Hain S; Boderet F; Bosq J; Emile JF; Le Deley MC; Capdeville R; Vassal G;
    Eur J Cancer; 2009 Sep; 45(13):2342-51. PubMed ID: 19362466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
    van Oosterom AT; Judson IR; Verweij J; Stroobants S; Dumez H; Donato di Paola E; Sciot R; Van Glabbeke M; Dimitrijevic S; Nielsen OS;
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S83-7. PubMed ID: 12528778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.